Cabotegravir injection for preventing HIV in pregnancy is safe, study finds

Long-acting injectable cabotegravir for HIV prevention deemed safe during pregnancy in global study among cisgender women.

Long-acting injectable cabotegravir (CAB-LA) was found to be safe and well-tolerated as HIV pre-exposure prophylaxis (PrEP) during pregnancy among cisgender women.
The study involved over 300 pregnancies and infants, with results to be presented at the 2024 International AIDS Conference in Munich, Germany.
The incidence of pregnancy-related adverse events was similar across groups using CAB-LA during pregnancy, prior to pregnancy, or no CAB-LA use.
Adverse infant outcomes were also similar across groups, with no significant differences in negative outcomes.
The study found that CAB-LA was safe and well tolerated for use before and during pregnancy, helping to address the need for effective HIV prevention options among cisgender women.

Study reveals dangerous microbes found in 7 billion tons of plastic waste